XML 35 R15.htm IDEA: XBRL DOCUMENT
v3.19.3

Earnings Per Share | 9 Months Ended
--- | ---
Sep. 30, 2019
Earnings Per Share [Abstract] |
Earnings Per Share | Earnings Per Share Basic earnings per share (“basic EPS”) is computed by dividing net income by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding resulting from employee stock options, restricted stock units, performance share units and stock appreciation rights ("SARs") during the period. The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2019 and 2018:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
Net income | $ | 6,970 |  |  | $ | 5,825 |  |  | $ | 13,686 |  |  | $ | 25,201 |
Basic – weighted average shares outstanding | 28,353 |  |  | 28,124 |  |  | 28,280 |  |  | 28,096 |
Effect of dilutive potential securities | 1,439 |  |  | 964 |  |  | 1,074 |  |  | 776 |
Diluted – weighted average shares outstanding | 29,792 |  |  | 29,088 |  |  | 29,354 |  |  | 28,872 |
Net income (per share) |  |  |  |  |  |  |  |  |  |  |
Basic | $ | 0.25 |  |  | $ | 0.21 |  |  | $ | 0.48 |  |  | $ | 0.90 |
Diluted | 0.23 |  |  | 0.20 |  |  | 0.47 |  |  | 0.87 |
The shares used in the calculation of diluted EPS exclude options and SARs to purchase shares where the exercise price was greater than the average market price of common shares for the period and the effect of the inclusion would be anti-dilutive. Such shares aggregated approximately 0.8 million and 0.7 million for the three and nine months ended September 30, 2019, respectively, and 0.0 million and 0.6 million for the three and nine months ended September 30, 2018, respectively. As more fully described in Note 17, our 2.625% convertible notes due in 2024 (the “Notes”) are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock. The calculation of diluted EPS would include potential diluted shares upon conversion of the Notes when the average market price per share of our common stock for the period, is greater than the conversion price of the Notes of $88.80. We intend to settle in cash the principal outstanding and use the treasury stock method when calculating their potential dilutive effect, if any. We have entered into convertible note hedge transactions to increase the effective conversion price of the Notes to $114.92. However, our convertible note hedges are not included when calculating potential dilutive shares since their effect is always anti-dilutive. During the three months ended September 30, 2019, our average share price exceeded the conversion price of the Notes and we included 0.2 million shares assumed to be issued if the Notes were converted in our diluted share count. During the nine months ended September 30, 2019 our average share price has not exceeded the conversion price of the Notes; therefore, under the net share settlement method, there were no potential shares issuable under the Notes to be used in the calculation of diluted EPS.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration